Last $55.33 USD
Change Today +2.02 / 3.79%
Volume 538.8K
ALNY On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 5:20 PM 07/29/14 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Barry E. Greene

President and Chief Operating Officer, Alnylam Pharmaceuticals, Inc.
AgeTotal Calculated CompensationThis person is connected to 40 board members in 3 different organizations across 6 different industries.

See Board Relationships
51$3,983,372
As of Fiscal Year 2013

Background*

Mr. Barry E. Greene has been the President and Chief Operating Officer at Alnylam Pharmaceuticals, Inc. since December 12, 2007 and October 2003 respectively. Mr. Greene has more than 20 years of experience in the healthcare, pharmaceutical and biotechnology industries. Mr. Greene joined Alnylam in 2003 and has over 15 years of experience in the healthcare industry. He served as the Principal Financial Officer and Principal Accounting Officer of Alnylam Pharmaceuticals ...

Read Full Background

Corporate Headquarters*

300 Third Street
Cambridge, Massachusetts 02142

United States

Phone: 617-551-8200
Fax: 617-551-8101

Board Members Memberships*

2007-Present
Director, Member of Compliance Committee and Member of Compensation Committee
2009-2012
Former Director and Member of Nominating & Corporate Governance Committee
2011-2012
Former Director
2013-Present
Director, Chairman of Compensation Committee and Member of Audit Committee
2014-Present
Director

Education*

BS
University of Pittsburgh

Other Affiliations*

Annual Compensation*

Salary$500,000
Total Annual Compensation$500,000

Stock Options*

All Other Compensation$7,746
Exercised Options82,080
Exercised Options Value$2,410,059
Exercisable Options593,800
Unexercisable Options240,000
Total Value of Options$2,410,059
Total Number of Options960,880

Total Compensation*

Total Annual Cash Compensation$776,496
Total Short Term Compensation$500,000
Other Long Term Compensation$7,746
Total Calculated Compensation$3,983,372
*Data is at least as current as the most recent Definitive Proxy.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ALNY:US $55.33 USD +2.02

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
Ali Mortazavi Chief Executive and Director
Silence Therapeutics plc
70.0K GBP
Hans G. C. P. Schikan Chief Executive Officer and Member of Management Board
Prosensa Holding N.V.
--
Mark J. Ahn Ph.D.Chief Executive Officer, President, Director and Member of Ad Hoc (Strategy, Pricing, Etc) Committee
Galena Biopharma, Inc.
$737.0K
Mark J. Murray Ph.D.Chief Executive Officer, President and Director
Tekmira Pharmaceuticals Corporation
$377.5K
Kleanthis G. Xanthopoulos Ph.D.Chief Executive Officer, President, Principal Financial & Accounting Officer and Director
Regulus Therapeutics Inc.
$600.0K
Compensation as of Fiscal Year 2013.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ALNYLAM PHARMACEUTICALS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.